ALLERGAN Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALLERGAN, and when can generic versions of ALLERGAN drugs launch?
ALLERGAN has seventy-three approved drugs.
There are nine US patents protecting ALLERGAN drugs.
There are one hundred and eighty-one patent family members on ALLERGAN drugs in fifty-five countries and one hundred and seventeen supplementary protection certificates in eighteen countries.
Summary for ALLERGAN
| International Patents: | 181 |
| US Patents: | 9 |
| Tradenames: | 70 |
| Ingredients: | 54 |
| NDAs: | 73 |
| Patent Litigation for ALLERGAN: | See patent lawsuits for ALLERGAN |
| PTAB Cases with ALLERGAN as patent owner: | See PTAB cases with ALLERGAN as patent owner |
Drugs and US Patents for ALLERGAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | ALBALON | naphazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 080248-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Allergan | THYROLAR-5 | liotrix (t4;t3) | TABLET;ORAL | 016807-006 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Allergan | KADIAN | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 020616-010 | Jul 9, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Allergan | OPTICROM | cromolyn sodium | SOLUTION/DROPS;OPHTHALMIC | 018155-001 | Oct 3, 1984 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALLERGAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-001 | Oct 8, 2008 | 6,015,819 | ⤷ Sign Up |
| Allergan | OPTICROM | cromolyn sodium | SOLUTION/DROPS;OPHTHALMIC | 018155-001 | Oct 3, 1984 | 4,053,628 | ⤷ Sign Up |
| Allergan | GELNIQUE 3% | oxybutynin | GEL, METERED;TRANSDERMAL | 202513-001 | Dec 7, 2011 | 7,198,801 | ⤷ Sign Up |
| Allergan | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-002 | Oct 8, 2008 | 5,387,603 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALLERGAN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 4 mg and 8 mg | ➤ Subscribe | 2012-10-09 |
| ➤ Subscribe | Ophthalmic Solution | 0.05% | ➤ Subscribe | 2008-10-14 |
| ➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2007-10-16 |
| ➤ Subscribe | Sublingual Tablets | 5 mg and 10 mg | ➤ Subscribe | 2013-08-13 |
| ➤ Subscribe | Extended-release Capsules | 60 mg | ➤ Subscribe | 2009-03-02 |
| ➤ Subscribe | Transdermal System Extended-re | 3.9 mg/24 hrs | ➤ Subscribe | 2008-08-19 |
| ➤ Subscribe | Ophthalmic Solution | 0.30% | ➤ Subscribe | 2007-07-19 |
| ➤ Subscribe | Tablets | 2.5 mg, 5 mg, 10 mg, and 20 mg | ➤ Subscribe | 2011-12-19 |
| ➤ Subscribe | Sublingual Tablets | 2.5 mg | ➤ Subscribe | 2017-07-27 |
International Patents for ALLERGAN Drugs
Supplementary Protection Certificates for ALLERGAN Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1534313 | 300784 | Netherlands | ⤷ Sign Up | PRODUCT NAME: KETOROLAC, OF HET TROMETAMOLZOUT ERVAN, EN FENYLEFRINE, OF HET HYDROCHLORIDEZOUT ERVAN; REGISTRATION NO/DATE: EU/1/15/1018 20150730 |
| 1304992 | 132013902214376 | Italy | ⤷ Sign Up | PRODUCT NAME: CLINDAMICINA FOSFATO E TRETINOINA(ACNATAC); AUTHORISATION NUMBER(S) AND DATE(S): PA1332/043/001, 20130322;042056010/M - 022/M, 20130718 |
| 0392059 | SPC/GB02/046 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515 |
| 1480644 | C20160041 00213 | Estonia | ⤷ Sign Up | PRODUCT NAME: TSEFTASIDIIM/AVIBAKTAAM;REG NO/DATE: EU/1/16/1109 28.06.2016 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
